<DOC>
	<DOC>NCT00212641</DOC>
	<brief_summary>The objectives of this study are to characterize the pharmacodynamic profile, safety and tolerability of ONO-5129 in patients with Type 2 Diabetes mellitus</brief_summary>
	<brief_title>A Phase II Study to Evaluate the Effects of Oral ONO-5129 in Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>1. Type 2 Diabetes Mellitus 2. FBG level &gt; 140 mg/dL and &lt; 270 mg/dL 3. Fasting TG level &lt; 500 mg/dL 4. BMI of 22 to 40 kg/m2, inclusive 5. Other Inclusion criteria as specified in the study protocol 1. Previous participation in an ONO5129 protocol 2. Previous treatment with TZD agents or other current antidiabetics 3. History of myocardial infarction, coronary artery surgery, atrial/ventricular tachycardia, or atrial/ventricular fibrillation in the past six months 4. Presence of functional limitations due to cardiovascular disease in accordance with the New York Heart Association Classification System Class III (moderate) or IV (severe) 5. Other exclusion criteria as specified in the study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>